BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Chronic lymphocytic leukemia clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for chronic lymphocytic leukemia: 149 (67 sponsors; 9 newly posted in the last 180 days, 3 stopped in the last 180 days; 5 new-entrant sponsors). Momentum score 12.1, rank 57 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 37, Phase 2 49, Phase 3 34, Phase 4 5, N/A 23.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| BeOne Medicines ONC | 10 | P3 6, P2 4 | 0 | 1 |
| Loxo Oncology, Inc. | 5 | P3 4, P2 1 | 0 | 0 |
| AstraZeneca AZN | 17 | NA 9, P3 3, P2 4, P4 1 | 0 | 5 |
| Acerta Pharma BV | 8 | P3 3, P2 3, P1 2 | 0 | 1 |
| Merck Sharp & Dohme LLC MRK | 6 | P3 3, P2 3 | 1 | 0 |
| AbbVie ABBV | 11 | P2 2, P1 4, P3 2, NA 3 | 0 | 1 |
| Ascentage Pharma Group Inc. AAPG | 8 | P3 2, P1 4, P2 2 | 0 | 2 |
| Janssen Research & Development, LLC | 6 | NA 1, P3 2, P2 1, P1 2 | 1 | 1 |
| Nurix Therapeutics, Inc. NRIX | 5 | P1 2, P2 2, P3 1 | 0 | 1 |
| Dizal Pharmaceuticals | 3 | P3 1, P2 2 | 0 | 0 |
| BeiGene | 2 | P3 1, P2 1 | 0 | 0 |
| Newave Pharmaceutical Inc | 2 | P1 1, P3 1 | 0 | 1 |
| Beijing InnoCare Pharma Tech Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| CSL Behring new entrant | 1 | P3 1 | 1 | 0 |
| Grifols Biologicals, LLC GRFS | 1 | P3 1 | 0 | 0 |
| Grifols Therapeutics LLC GRFS | 1 | P3 1 | 0 | 0 |
| Eli Lilly and Company LLY | 4 | P2 1, P4 3 | 0 | 0 |
| Genmab GMAB | 3 | P2 3 | 0 | 0 |
| Ossium Health, Inc. | 3 | NA 2, P2 1 | 1 | 0 |
| Bristol-Myers Squibb BMY | 2 | NA 1, P1 1 | 0 | 1 |
| Guangzhou Lupeng Pharmaceutical Company LTD. new entrant | 2 | P2 2 | 2 | 0 |
| iOMEDICO AG | 2 | NA 2 | 0 | 0 |
| Miltenyi Biomedicine GmbH | 2 | P1 1, NA 1 | 0 | 0 |
| Accutar Biotechnology Inc | 1 | P1 1 | 0 | 0 |
New-entrant sponsors: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSL Behring, Guangzhou Lupeng Pharmaceutical Company LTD..
Recently stopped trials
- NCT05828589 BeOne Medicines - terminated: This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driv A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
- NCT06561425 Lakefront Biotherapeutics NV - terminated: Following the decision by Galapagos NV to wind down its cell therapy programs, the study was early terminated at the end of the study treatm A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
- NCT05515406 Ono Pharmaceutical Co., Ltd. - terminated: The study was terminated due to a strategic decision to discontinue development. A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Ascentage Pharma Group Inc. AAPG | NCT05147467 Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | recruiting | 75 |
| 2026-12-31 est. | P3 | Janssen Research & Development, LLC | NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; | active not recruiting | 539 |
| 2026-12-31 est. | P3 | Ascentage Pharma Group Inc. AAPG | NCT06104566 Global Trial in APG2575 for Patients With CLL/SLL | CLL/SLL | recruiting | 400 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | BeOne Medicines ONC | NCT06637501 A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | active not recruiting | 94 |
| 2026-11 est. | P2 | AbbVie ABBV | NCT04895436 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic | Chronic Lymphocytic Leukemia (CLL) | recruiting | 75 |
| 2026-10-28 | P2 | Genentech, Inc. | NCT06524375 A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic | Chronic Lymphocytic Leukemia | active not recruiting | 118 |
| 2026-10 est. | P3 | Loxo Oncology, Inc. | NCT04965493 A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/ | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | active not recruiting | 600 |
| 2026-07-14 | P1/P2 | Ossium Health, Inc. | NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malign | Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Biphenotypic Leukemia; A | active not recruiting | 12 |
| 2026-06-22 est. | P2 | Cellectar Biosciences, Inc. CLRB | NCT02952508 Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom | Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lym | active not recruiting | 120 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "chronic lymphocytic leukemia"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.